Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

EXaSCale smArt pLatform Against paThogEns for Corona Virus

Projektbeschreibung

Computergestützte Entwicklung von COVID-19-Medikamenten

Die fortgeschrittene computergestützte Entwicklung von Medikamenten hat die Wirkstoffforschung revolutioniert. In Verbindung mit biochemischem und phänotypischem Hochdurchsatz-Screening wird so die zügige Entwicklung neuer Arzneimittel ermöglicht. Das Forschungsteam des EU-finanzierten Projekts EXSCALATE4CoV wird mithilfe der Plattform EXSCALATE, die die vielversprechendsten, für den Menschen sicheren kommerziellen Arzneimittel umfasst, spezifische Hemmstoffe für COVID-19 ermitteln. Die Strategie beinhaltet den computergestützten Abgleich dieser Arzneimittel mit 3D-Modellen für die viralen Proteine, gefolgt von biochemischen Assays und phänotypischen Screenings der aussichtsreichsten Kandidaten. Moleküle, mit denen sich die Virusreplikation blockieren lässt, werden anschließend zur weiteren Entwicklung und zur Zulassung weitergeleitet.

Ziel

The EXSCALATE4CoV (E4C) project aims to exploit the most powerful computing resources currently based in Europe to empower smart in-silico drug design. Advanced Computer-Aided Drug Design (CADD) in combination with the high throughput biochemical and phenotypic screening will allow the rapid evaluation of the simulations results and the reduction of time for the discovery of new drugs. Against a pandemic crisis, the immediate identification of effective treatments have a paramount importance. First, E4C will select through the EXSCALATE platform, the most promising commercialized and developing drugs safe in man. Second, select from >500 billion molecules new pan coronavirus inhibitors. The huge computational resource, therefore the activities will be supported and empowered by three of the most powerful computer centers in Europe: CINECA, BSC and JÜLICH. The Swiss Institute of Bioinformatics (SIB) will provide the homology 3D models for the viral proteins. The Fraunhofer IME will provide the BROAD Repurposing Library and biochemical assays. Phenotypic screenings will be run by KU LUEVEN to identify molecules capable of blocking virus replication in in vitro models. IIMCB and ELECTRA will determine the crystal structure of at least one coronavirus functional proteins to evaluate the structural similarities with other viral proteins. EXSCALATE4CoV consortium will identify safe in man drugs repurposed as 2019-nCoV antiviral and will propose to the EMA innovation task force (ITF) to define a preliminary development strategy and a proposal for a registration path. The E4C project will share promptly its scientific outcomes with the research community by using established channels: ChEMBL portal for the biochemical data, the SWISS-MODEL portal for the homology models of viral proteins WT and mutants, the Protein Data Bank for the experimentally resolved protein structures, the EUDAT for the data generated by in-silico simulations and the E4C project website.

Koordinator

DOMPE FARMACEUTICI SPA
Netto-EU-Beitrag
€ 409 375,00
Adresse
VIA S MARTINO DELLA BATTAGLIA 12
20122 Milano
Italien

Auf der Karte ansehen

Region
Nord-Ovest Lombardia Milano
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 409 375,00

Beteiligte (17)